Published in final edited form as:

Clin Cancer Res. 2019 September 01; 25(17): 5242–5249. doi:10.1158/1078-0432.CCR-19-0566.

Distinguishing tumor from associated fibrosis to increase diagnostic biopsy yield with polarization-sensitive optical coherence tomography

Lida P. Hariri^{1,2,3,4,*}, David C. Adams^{1,3,4}, Matthew B. Applegate^{1,3}, Alyssa J. Miller^{1,3}, Benjamin W. Roop^{1,3}, Martin Villiger^{3,4}, Brett E. Bouma^{3,4}, Melissa J. Suter^{1,3,4,*}

¹Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital

²Department of Pathology, Massachusetts General Hospital

³Wellman Center for Photomedicine, Massachusetts General Hospital

⁴Harvard Medical School, Boston, MA

Abstract

Purpose: With recent advancements in personalized medicine, biopsies must contain sufficient tumor for histological diagnosis and molecular testing. However, inadvertent biopsy of tumor-associated fibrosis compromises tumor yield, resulting in delayed diagnoses and/or repeat procedures when additional tumor is needed. The ability to differentiate tumor from fibrosis intraprocedurally during biopsy could significantly increase tumor yield. Polarization sensitive optical coherence tomography (PS-OCT) is an imaging modality that is endoscope and/or needle-compatible, and provides large volumetric views of tissue microstructure with high resolution (~10 μ m) while simultaneously measuring birefringence of organized tissues such as collagen. We aim to determine whether PS-OCT can accurately detect and distinguish tumor-associated fibrosis from tumor.

Experimental Design: PS-OCT was obtained *ex vivo* in 64 lung nodule samples. PS-OCT birefringence was measured and correlated to collagen content in precisely matched histology, quantified on picrosirius red (PSR) staining.

*Corresponding Authors: Melissa J. Suter, Ph.D., 55 Fruit St., Warren Building Room 407. Boston, MA 02114, msuter@partners.org, Phone: 617-724-7691 Fax: 617-726-4103; Lida P. Hariri, M.D., Ph.D., 55 Fruit St., Warren Building Room 407. Boston, MA 02114, lhariri@mgh.harvard.edu, Phone: 617-726-6566 Fax: 617-726-4103.

Conflicts of Interest:

Dr. Lida Hariri: Dr. Hariri is a consultant for LX Medical.

Dr. David C. Adams: No conflicts of interest.

Dr. Matthew Applegate: No conflicts of interest.

Ms. Alyssa J. Miller: No conflicts of interest.

Mr. Benjamin Roop: No conflicts of interest.

Dr. Martin Villiger: No conflicts of interest.

Dr. Brett E. Bouma receives consulting income from NinePoint Medical. NinePoint Medical has a licensing arrangement with MGH.

Dr. Bouma has the right to receive royalty payments from NinePoint.

Dr. Melissa Suter is an author on Massachusetts General Hospital owned patents that have been licensed to NinePoint Medical. Dr.

Suter has the rights to receive royalties from these licensing arrangements. Dr. Suter was a past consultant for NinePoint Medical, and for LX Medical.

Results: There was a strong positive correlation between PS-OCT measurement of birefringent fibrosis and total collagen content by PSR ($r = 0.793$, $p < 0.001$). In addition, PS-OCT was able to accurately classify tumor regions with $> 20\%$ fibrosis from those with low fibrosis ($< 20\%$) that would likely yield higher tumor content ($p < 0.0001$).

Conclusions: PS-OCT enables accurate fibrosis detection and can distinguish tumor regions with low fibrosis. PS-OCT has significant potential for clinical impact, as the ability to differentiate tumor from fibrosis could be used to guide intraprocedural tissue sampling *in vivo*, or for rapid biopsy adequacy assessment *ex vivo*, to increase diagnostic tumor yield essential for patient care and research.

Keywords

Stromal fibrosis; Desmoplasia; Lung carcinoma; Lung cancer; Biopsy guidance; Fine needle aspiration guidance; Optical coherence tomography; Optical frequency domain imaging; Birefringence polarimetry

Introduction

Tissue biopsy is the principal method used to diagnose tumors in a variety of organ systems. It is essential to maximize tumor yield in biopsy specimens for both clinical and research purposes. This is especially imperative in clinical scenarios requiring chemotherapy and/or radiation therapy, neoadjuvant or otherwise, where biopsy is the sole source of tumor tissue from a patient. This is also of significant importance in tumors where adequate tissue is needed for: 1) diagnosis, requiring hematoxylin and eosin (H&E) and possibly immunohistochemical stains for accurate tumor subtyping, and 2) molecular testing to identify patients who may benefit from mutation-specific targeted therapy, such as in lung adenocarcinomas (1-6). Most carcinomas contain a mixture of tumor and other non-tumor elements, such as stromal fibrosis, which is seen prominently in lung, breast, and pancreatic carcinomas. Inadvertent sampling of fibrotic tissue contaminates biopsies, decreases tumor yield, and can even impede diagnosis (5-7). Correspondingly, tumor collection for research purposes, such as biobanking and establishment of patient-derived primary tumor cell lines, are more likely to be successful when samples contain maximal tumor tissue (8). Fibrotic stroma is a known, challenging contaminant in research specimens. This contamination is vexing due to the abundant resources used to procure and store these sample collections and the reliance on ample tumor cell collection for execution of successful research studies.

Due to significant advancements in personalized medicine in lung carcinomas, there have been major efforts to maximize tumor yield in lung nodule biopsy (1-6). Guidance techniques, such as endobronchial ultrasound (EBUS), electromagnetic navigation (EMN), and CT-guided transthoracic biopsy, have been developed to help guide biopsy tools to the location of a targeted nodule in order to improve yield (2,3,9-11). However, these techniques do not provide insight into tumor composition, and therefore, cannot distinguish regions of tumor from admixed contaminant fibrotic stroma. Rapid On-Site Evaluation (ROSE) of fine needle aspiration (FNA) cytology has been implemented to improve yields in lung nodule biopsy, which has been effective but has limitations. ROSE is a retrospective assessment of collected FNA tissues, and as a result, is susceptible to false negative reads due to biopsy

sampling error. ROSE cannot reliably quantify tumor amount on FNA, and rapid assessment of core biopsy tumor content is problematic due to consumption of tumor during frozen section assessment or touch prep (12). When there is inadequate tumor on initial biopsy, patients often must undergo repeat biopsy or more invasive procedures, such as video-assisted thoracoscopic surgical (VATS) wedge resection, to obtain additional material.

There is a clear need to optimize tumor yield and minimize contaminant fibrosis in biopsy specimens. Optical coherence tomography (OCT) is a non-destructive optical imaging modality that provides rapid, large volume, depth-resolved (~1–2 mm penetration depth depending on tissue scatter properties), high-resolution (<10 μ m) images of tissue microstructure (13,14). OCT has been successfully applied to disease detection in many organ systems, including the cardiovascular, gastrointestinal, ocular, and pulmonary systems (15-25). OCT imaging can be employed for either *in vivo* or *ex vivo* microarchitectural tissue assessment. In the pulmonary tract, both endobronchial and needle-based OCT catheters, compatible with standard bronchoscopy and transbronchial needles, have been developed that could be used for rapid, intraprocedural imaging of tissues surrounding the needle immediately prior to sample collection (26-28). Benchtop OCT systems can also be readily used for rapid *ex vivo* assessment of collected tissue specimens, including biopsy samples and resection specimens (29).

OCT has been shown capable of assessing and distinguishing lung parenchyma from pulmonary nodules with > 90% sensitivity and specificity, which has potential to improve diagnostic yield by providing microscopic guidance for needle biopsy as a complement to macroscopic guidance techniques such as EBUS and EMN (23,24). However, the ability to distinguish tumor from admixed non-diagnostic fibrosis is crucial to the utility of OCT in guiding biopsy site selection and increasing tumor yield (25). Linearly organized tissues, such as collagen in fibrosis, demonstrate birefringence signatures (30,31). Polarization sensitive OCT (PS-OCT) is a modification to traditional OCT that detects tissue birefringence while simultaneously generating structural OCT images, and therefore, provides a means to detect fibrosis (31-35). Many groups, including ours, have shown that PS-OCT has potential to distinguish birefringent fibrosis from other tissue types, including tumors of the skin, larynx, breast, and lung (25,36-42), but the majority of these studies have been qualitative in nature. Nadkarni et al. demonstrated that PS-OCT can be used to accurately quantify collagen in coronary atherosclerotic plaques to assist in intracoronary plaque assessment (31). Similar quantitative validation studies are foundational to assessing the true clinical potential of PS-OCT in tumor assessment and biopsy guidance. In this study, we investigate the ability of PS-OCT to quantify fibrotic stroma and distinguish low versus high fibrosis content in primary lung tumors.

Methods

Benchtop PS-OCT imaging was performed in a total of 64 tumor samples from fresh *ex vivo* lung resection specimens obtained from 26 patients. The Partners Healthcare Institutional Review Board (IRB) approved this study (Protocol Number: 2010-P-002214/1). Studies were conducted in accordance with the Ethical Principles and Guidelines for the Protection of Human Subjects of Research, known as the Belmont Report. The informed written

consent process was waived due to the use of de-identified excess tissue in this study, as approved by the Partners IRB. To ensure accurate registration with histology, regions of interest were demarcated in tissue samples using two needle marks (26-gauge) and tissue marking dye (Triangle Biomedical Sciences, Durham, NC) visible in both PS-OCT imaging and histology. For each PS-OCT and histology pair, the region of interest was precisely registered based on the location of the inked needle marks. The details of the ink mark registration procedure have previously been described in detail (43).

PS-OCT imaging, processing and birefringence calculation

The technical details of the PS-OCT system and methods used in this study to generate PS-OCT images have been previously described in detail (14,22,32-35,44-46). Briefly, we used a custom-built fiber-based swept-source OCT system with a center wavelength of 1310 nm, a bandwidth of 110 nm, and an A-line acquisition rate of 66 kHz. A benchtop microscope, with a telecentric lens with a spot size approximately 20 μm , was used to image the tissue samples. The axial resolution of the OCT system was approximately 7 μm in tissue. Lateral and transverse scanning were achieved using galvanometric mirrors.

Conventional structural OCT and PS-OCT images were obtained simultaneously, and images were generated from the raw datasets off-line. Structural OCT images were processed and displayed by use of an inverse gray-scale lookup table. Polarization sensitivity was achieved by modulating the polarization state of the source between perpendicular polarization states in successive axial depth profiles (A-lines), then combining A-line pairs by Stokes vector analysis (22,32-35,46). PS-OCT images were processed using a spectral binning method to mitigate polarization mode dispersion, which has previously been described in detail (46). Differential (local) retardation was calculated from spectrally binned data using a depth offset of approximately 24 μm (in tissue).

Out of frame averaging was performed on OCT images over 30 frames, or approximately 60 μm , to reduce speckle noise. Structural OCT images were thresholded to remove signal < 30 dB in order to remove noise. PS-OCT birefringence was thresholded to remove signal < 20 degrees/100 microns, based on birefringence values from previously published data (22). The thresholded structural image was then used to mask the corresponding thresholded PS-OCT image to isolate birefringence signal arising from tissue. The PS-OCT region of interest (ROI) was defined as the distance between the two registration ink marks (ranging 2.6–8.8 mm) by 0.25 mm depth. The depth of 0.25 mm was chosen to mitigate signal roll off within tissue. The percent fibrosis in the PS-OCT ROI was calculated as the number of pixels with birefringence measurements > 20 degrees/100 microns divided by the total number of pixels in the ROI. All data processing was performed using Matlab (Natick, MA).

Histologic Analysis of Fibrosis

Following imaging, the tissue specimens were fixed in 10% formalin and processed using standard histology techniques. Tissue sections (5 μm thick) were cut cross-sectionally, traversing the registration ink marks. Sequential sections were stained with hematoxylin and eosin (H&E) or picrosirius red (PSR), a stain for collagen (47,48). Collagen content was measured within the PSR ROI morphometrically using digitized images of the PSR stained

sections, obtained with a circularly polarized light microscope (Olympus BX43, Olympus America, Center Valley, PA). The camera exposure time was set to prevent saturation and was kept constant for all cases at 60 ms, with zero gain. The PSR ROI was defined as the distance measured laterally between the ink marks (x-axis) by 0.25 mm in depth (y-axis) on one PSR slide, corresponding to the PS-OCT ROI. Collagen fibers in PSR visualized under polarized light microscopy appear as either orange-red or yellow-green, depending on fiber thickness. Collagen fibers were identified in PSR images based on the corresponding hue values, after a saturation threshold of 25 was applied to remove noise. Total collagen content was computed by dividing the number of pixels corresponding to collagen fibers (hue values in Red/Orange: 1–38, 230–256, or yellow-green: 39–128) by the total number of pixels in the ROI. This method has been previously described in detail (31,47,48).

Statistical Analysis

Linear regression analysis was performed to test the correlation between PS-OCT birefringence imaging and histologic PSR collagen measurements in matched ROIs. Fisher's exact test was performed to determine the ability of PS-OCT to distinguish tumor regions with low fibrosis content ($\leq 20\%$) from tumor regions with $> 20\%$ fibrosis. A 20% cut-off was chosen to determine whether PS-OCT could accurately identify tumor-rich regions likely to yield high tumor sampling. Bland-Altman analysis was performed to compare the amount of measured collagen for the two measuring techniques. The difference was calculated as the percent collagen measured by PSR minus the percent collagen detected by PS-OCT in matched ROIs. For all analyses, a p value of < 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad (La Jolla, CA).

Results

Histology

PS-OCT was obtained from 64 tumor samples (31 adenocarcinomas, 30 squamous cell carcinomas (SCC), 2 carcinoid tumors, 1 hamartoma) from *ex vivo* lung resection specimens from 26 patients. Of these, 7 samples from 3 patients were removed from the analysis due to issues with ink marks prohibiting accurate PS-OCT:histology matching (n=3), or technical issues with PS-OCT data acquisition (n=4). The remaining 57 samples from 23 patients were included in the testing dataset (Table 1).

PS-OCT fibrosis detection

Total collagen content measured morphometrically from PSR stained sections under polarized light microscopy ranged from 0.2 to 83.9% amongst the tumor samples. Linear regression analysis showed a strong positive correlation in total collagen detected in PS-OCT birefringence imaging and total collagen content measured by PSR ($r = 0.793$, $p < 0.001$), as demonstrated in Figure 1. Fisher's exact test demonstrated that PS-OCT was able to classify tumor regions with low fibrosis content ($\leq 20\%$) from those with $> 20\%$ fibrosis ($p < 0.0001$), as demonstrated in Table 2. The sensitivity and specificity of PS-OCT for low fibrosis tumor regions ($\leq 20\%$) was 0.95 and 0.80, respectively. The overall classification accuracy was 0.91. Bland-Altman analysis demonstrated an average bias of 3.898%, indicating that PSR measures more collagen than does PS-OCT. Bland-Altman

analysis on the low fibrosis group ($\leq 20\%$ fibrosis) demonstrated a bias of -0.338% (Figure 2), indicating that PS-OCT fibrosis detection is more accurate when there is low fibrosis content. Additional Fisher's exact test analyses with threshold cutoffs for low fibrosis set at 18.5% and 22.5% were also performed (Supplemental Tables 1 and 2), which yielded similar results ($p < 0.0001$ for both threshold values).

In addition to fibrosis quantification, PS-OCT also provides information about the microscopic distribution of fibrosis and tumor within lung nodules. Figure 3a-b shows an illustrative PS-OCT image of a squamous cell carcinoma (SCC) with regional dense fibrosis. In the right half of the ROI there is dense birefringent collagen visualized with PS-OCT, and confirmed by PSR staining, indicating the right side is not an ideal site for biopsy. However, the left side of the image contains little birefringent fibrosis, which indicates that this region is likely to yield more tumor in a biopsy sample. Figure 3c-d shows an illustrative PS-OCT image of an adenocarcinoma with focal fibrosis, occupying approximately 25% of the total ROI, which could be avoided during biopsy sampling. Corresponding PSR staining confirms the focus of fibrosis within the adenocarcinoma in the same ROI region. These two cases illustrate the ability of PS-OCT to detect contaminant fibrosis and provide microscopic spatial mapping of the tumor/fibrosis distribution within a nodule. This would be useful in guiding biopsy site sampling locations *in vivo* and tumor collection sites for molecular testing and/or biobanking *ex vivo*.

Figure 4a-b illustrates a non-invasive lepidic adenocarcinoma, with minimal fibrosis present within the alveolar walls throughout the ROI on PSR staining that is typical of this adenocarcinoma subtype histologically. The corresponding PS-OCT image demonstrates minimal interstitial birefringence throughout the ROI. Figure 4c-d shows an illustrative example of an SCC with solid morphology. Essentially no birefringent collagen was seen on PS-OCT imaging or PSR staining. These two cases illustrate the ability of PS-OCT to detect tumor regions with little to no contaminant fibrosis, indicating adequate biopsy site locations, as well as potential to provide some microarchitectural insights into morphologic patterns. Supplemental Figures 1-5 present additional examples of PS-OCT and PSR matched pairs from the dataset.

Discussion

Biopsy samples must have adequate tumor yields to satisfy both histological and molecular diagnostics, particularly in lung carcinomas. However, when inadequate tumor sampling occurs, it is often in large part from inadvertent biopsy of tumor-associated fibrosis within the lesion. In this study, we demonstrated that PS-OCT can accurately identify tumor-associated fibrosis, and distinguish it from tumor, using tissue birefringence detection. Our results demonstrate a strong correlation between PS-OCT birefringence and PSR histology measurement of fibrosis content. This validation study is an essential step in the clinical translation of the technology, which has significant potential for impact to increase tumor yield in a variety of clinical and research settings.

Physicians performing lung biopsies seek to obtain the highest possible tumor yield in the sample for current and potential future individual patient care needs, as well as potential

banking/research purposes (5,6). In a study examining the compositions of samples containing 30% tumor, 87.1% of the samples contained some amount of fibrosis, and 41.6% had fibrosis as their most abundant non-tumor component (7). PS-OCT could be implemented *in vivo* for intraprocedural biopsy guidance to avoid contaminant fibrosis and increase tumor yield. Needle-based OCT probes have been developed that are compatible with bronchoscopy and TBNA, which would allow PS-OCT imaging of tissues around the needle prior to sample collection (26-28). We have previously shown that structural OCT is capable of distinguishing lung nodules and lung parenchyma with high sensitivity and specificity (> 90%) and can be utilized to ensure accurate targeting of a nodule (23). The additional ability to distinguish tumor from adjacent fibrosis within the nodule has significant potential to increase tumor yield and reduce the need for repeat and/or more invasive procedures to acquire more tumor tissue.

In this study, we found that PS-OCT fibrosis detection was strongly correlated to PSR histology measurement of fibrosis content. Bland-Altman analysis revealed there was small bias such that overall, PSR detected more collagen than PS-OCT. However, within the low fibrosis group, the average difference between measurements was negligible (−0.338%), suggesting that both methods produce nearly identical results when measuring in low fibrosis content regions.

The results of our study are an essential step towards translating PS-OCT to the *in vivo* biopsy guidance setting. However, our findings must be validated in large-scale clinical studies. PS-OCT could also be implemented for *ex vivo* tissue assessment using benchtop imaging stations. Potential *ex vivo* applications include using PS-OCT for rapid adequacy assessment of biopsy specimens without consuming, freezing, or damaging tissue, or for selection of tissue for clinical purposes, biobanking, primary cell culture, or other research purposes, from either biopsy or whole lung resection specimens.

In addition to quantifying fibrosis, PS-OCT also provides the ability to visualize fibrosis distribution, which adds further benefit for guiding tumor sampling sites *in vivo* and *ex vivo*. This is exemplified in the illustrative cases in Figures 3-4. In Figure 3a-b, although the quantified fibrosis burden was high, PS-OCT revealed that dense fibrosis occupied predominantly the right half of the ROI. Tumor collection from the left half of the ROI would likely yield a successful sample. In Figure 3c-d, PS-OCT revealed that the majority of the ROI contained tumor, with only a focal region abundant in fibrosis that could be avoided during tumor biopsy/collection. PS-OCT also has the potential to inform on the underlying pattern of the carcinoma. In Figure 4a-b, PS-OCT demonstrated minimal interstitial fibrosis present throughout the ROI, reflecting the minimal alveolar wall fibrosis of lepidic adenocarcinoma and indicating that the entire ROI would be adequate for tumor biopsy/collection. In contrast, Figure 4c-d revealed a solid pattern of carcinoma with essentially no fibrosis within the ROI, providing information both on the suitability of the biopsy site as well as potential insights in to the tumor pattern present in the ROI.

For successful translation to clinical use, the data processing and analysis must be achievable within clinically acceptable timeframes. In this study, we used Matlab for PS-OCT image processing, which currently takes ~2 seconds/frame. The use of a more efficient

programming language would significantly speed up image processing times so that processing could be performed in real time. The PS-OCT fibrosis quantification process described in this study was nearly fully-automated, with processing rates of ~30 frames/second. This was also performed using Matlab, and could be sped up with another programming language if necessary. The only portion of the quantification algorithm that was performed manually was defining the lateral aspect (x-axis) of the ROI. This was not automated in this study because the lateral ROI distance was different for each sample (defined by the distance between the ink registration marks) in order to compare against the matched PSR ROI. In the clinical setting, a simple tissue surface identification algorithm would be sufficient. Our lab has already published automated methods for tissue surface identification, which could easily be applied to this setting (22,49).

This study focused on assessment of primary lung tumors, due to the eminent clinical necessity to increase tumor yield in order to meet histologic and molecular testing needs in lung carcinomas. However, fibrosis contamination in biopsies is known to occur in many other primary malignancy sites, such as breast and pancreatic carcinoma. Collagen present within tumors at other primary sites is anticipated to have similar organizational arrangements as seen in lung primary malignancies. Therefore, it is expected that fibrosis within other primary tumor sites would exhibit similar birefringence detectable by PS-OCT. Therefore, the ability to quantify fibrosis burden is likely to be translatable to other organ sites. Other groups have conducted pilot studies investigating PS-OCT for fibrosis detection in breast carcinoma (36-38) and the results of our study concur with their findings. However, follow-up studies are needed to confirm the translatability of our findings in other primary tumor sites. Fibrosis detection by PS-OCT also has potential to make significant clinical impacts in non-neoplastic disease entities such as fibrotic interstitial lung diseases including usual interstitial pneumonitis (21), airway changes in asthma (22), and skin fibrosis in systemic sclerosis.

Our data showed some trends where PS-OCT seemed to over-estimate at low collagen levels and under-estimate at high collagen levels. Samples with low collagen levels are more likely to contain younger, less organized, and/or less dense collagen, which will have lower birefringence signals that may be near the noise floor. It is possible that minor modifications to the noise floor threshold may assist in increasing the fibrosis detection accuracy in these cases. Although the PSR stain is the standard histologic stain for collagen detection, it has been described in the literature that PSR is an imperfect method for collagen quantification (50,51). It is possible that PSR underestimated collagen in the low fibrosis cases. Samples with high fibrosis levels may contain storiform patterns of dense collagen, which may include small regions where the fibers are oriented parallel to the incident OCT beam (see Supplemental Figure 5). When collagen is oriented parallel to the beam, birefringence will not be detected and therefore, total collagen content will be under-estimated. Registration between PS-OCT images and histology sections were performed by using ink marks to define the ROI, applied to the tissue using a 26 gauge needle. Therefore, the precision of the registration between PS-OCT and histology was ~500 μ m. Patterns of fibrosis are known to vary within tumor nodules, and lack of exact precision in PS-OCT and corresponding PSR matches may have led to differences in the amount of fibrosis measured by each modality.

Despite these limitations, the correlation between PS-OCT and PSR fibrosis detection was high.

In this study, we demonstrate that PS-OCT detection of birefringent collagen allows for accurate distinction of fibrosis and tumor within tumor nodules, which is an essential step in translating the technology for clinical use to increase tumor yield in biopsy specimens. We assessed PS-OCT imaging in *ex vivo* lung tumor nodules and compared fibrosis detection against corresponding histology stained with PSR, demonstrating high correlation between the two modalities. PS-OCT was able to reliably identify tumor regions with low fibrosis content (~ 20%). We anticipate that these findings will have significant potential for clinical applications, through *in vivo* needle-based PS-OCT imaging performed intraprocedurally to guide biopsy site selection and/or *ex vivo* benchtop PS-OCT imaging for rapid biopsy adequacy assessment or selection of biobanking/research tissues.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was funded in part by the National Institute of Health [Grant numbers R01CA167827, K23HL132120, T32CA009216], a grant from the LUNGEVITY Foundation/Upstage Lung Cancer [Grant number 2016-02], and a grant from the American Lung Association [RT-342501].

References

1. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6(2): 244–85 doi 10.1097/JTO.0b013e318206a221. [PubMed: 21252716]
2. Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132(3 Suppl):131s–48s doi 10.1378/chest.07-1357. [PubMed: 17873165]
3. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-Analysis of Guided Bronchoscopy for the Evaluation of the Pulmonary Nodule. *CHEST* 2011 doi 10.1378/chest.11-1764.
4. Simon GR, Silvestri GA. You just can't call it lung cancer anymore. *J Thorac Oncol*;6(2):239–40 doi 10.1097/JTO.0b013e31820bf5b801243894-201102000-00002 [pii].
5. Kerr KM. Personalized medicine for lung cancer: new challenges for pathology. *Histopathology* 2012;60(4):531–46 doi 10.1111/j.1365-2559.2011.03854.x. [PubMed: 21916947]
6. Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicolson MC, et al. Quantitative Analysis of Tumor in Bronchial Biopsy Specimens. *Journal of Thoracic Oncology* 2010;5(4):448–52 doi 10.1097/JTO.0b013e3181ca12c4. [PubMed: 20125040]
7. Goh F, Duhig EE, Clarke BE, McCaul E, Passmore L, Courtney D, et al. Low tumour cell content in a lung tumour bank: implications for molecular characterisation. *Pathology* 2017;49(6):611–7 doi 10.1016/j.pathol.2017.07.001. [PubMed: 28811084]
8. Massett HA, Atkinson NL, Weber D, Myles R, Ryan C, Grady M, et al. Assessing the need for a standardized cancer HUMAN Biobank (caHUB): findings from a national survey with cancer researchers. *J Natl Cancer Inst Monogr* 2011;2011(42):8–15 doi 10.1093/jncimonographs/igr007. [PubMed: 21672890]
9. Mazzone P, Jain P, Arroliga AC, Matthay RA. Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. *Clin Chest Med* 2002;23(1):137–58, ix. [PubMed: 11901908]

10. Shure D, Fedullo PF. Transbronchial needle aspiration of peripheral masses. *Am Rev Respir Dis* 1983;128(6):1090–2 doi 10.1164/arrd.1983.128.6.1090. [PubMed: 6650983]
11. Doms C, Seijo L, Gasparini S, Trisolini R, Ninane V, Tournoy KG. Diagnostic bronchoscopy: state of the art. *Eur Respir Rev*;19(117):229–36 doi 19/117/229 [pii] 10.1183/09059180.00005710.
12. da Cunha Santos G, Ko HM, Saieg MA, Geddie WR. “The petals and thorns” of ROSE (rapid on-site evaluation). *Cancer Cytopathol* 2013;121(1):4–8 doi 10.1002/cncy.21215. [PubMed: 22760969]
13. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. *Science* 1991;254(5035):1178–81. [PubMed: 1957169]
14. Yun SH, Tearney GJ, Vakoc BJ, Shishkov M, Oh WY, Desjardins AE, et al. Comprehensive volumetric optical microscopy in vivo. *Nat Med* 2006;12(12):1429–33 doi 10.1038/nm1450. [PubMed: 17115049]
15. Tearney GJ, Waxman S, Shishkov M, Vakoc BJ, Suter MJ, Freilich MI, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. *JACC Cardiovascular imaging* 2008;1(6):752–61 doi 10.1016/j.jcmg.2008.06.007. [PubMed: 19356512]
16. Suter MJ, Vakoc BJ, Yachimski PS, Shishkov M, Lauwers GY, Mino-Kenudson M, et al. Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging. *Gastrointestinal endoscopy* 2008;68(4):745–53 doi 10.1016/j.gie.2008.05.014. [PubMed: 18926183]
17. Hee MR, Izatt JA, Swanson EA, et al. Optical coherence tomography of the human retina. *Archives of Ophthalmology* 1995;113(3):325–32 doi 10.1001/archoph.1995.01100030081025. [PubMed: 7887846]
18. Michel RG, Kinasevitz GT, Fung KM, Keddisi JI. Optical coherence tomography as an adjunct to flexible bronchoscopy in the diagnosis of lung cancer: a pilot study. *Chest* 2010;138(4):984–8 doi 10.1378/chest.10-0753. [PubMed: 20472863]
19. Tsuboi M, Hayashi A, Ikeda N, Honda H, Kato Y, Ichinose S, et al. Optical coherence tomography in the diagnosis of bronchial lesions. *Lung Cancer* 2005;49(3):387–94 doi 10.1016/j.lungcan.2005.04.007. [PubMed: 15922488]
20. Lam S, Standish B, Baldwin C, McWilliams A, leRiche J, Gazdar A, et al. In vivo optical coherence tomography imaging of preinvasive bronchial lesions. *Clin Cancer Res* 2008;14(7):2006–11 doi 10.1158/1078-0432.Ccr-07-4418. [PubMed: 18381938]
21. Hariri LP, Adams DC, Wain JC, Lanuti M, Muniappan A, Sharma A, et al. Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of Idiopathic Pulmonary Fibrosis In Vivo. *Am J Respir Crit Care Med* 2018;197(7):949–52 doi 10.1164/rccm.201707-1446LE. [PubMed: 28934552]
22. Adams DC, Hariri LP, Miller AJ, Wang Y, Cho JL, Villiger M, et al. Birefringence microscopy platform for assessing airway smooth muscle structure and function in vivo. *Sci Transl Med* 2016;8(359):359ra131 doi 10.1126/scitranslmed.aag1424.
23. Hariri LP, Mino-Kenudson M, Applegate MB, Mark EJ, Tearney GJ, Lanuti M, et al. Toward the guidance of transbronchial biopsy: identifying pulmonary nodules with optical coherence tomography. *Chest* 2013;144(4):1261–8 doi 10.1378/chest.13-0534. [PubMed: 23828441]
24. Hariri LP, Applegate MB, Mino-Kenudson M, Mark EJ, Medoff BD, Luster AD, et al. Volumetric optical frequency domain imaging of pulmonary pathology with precise correlation to histopathology. *Chest* 2013;143(1):64–74 doi 10.1378/chest.11-2797. [PubMed: 22459781]
25. Hariri LP, Villiger M, Applegate MB, Mino-Kenudson M, Mark EJ, Bouma BE, et al. Seeing beyond the Bronchoscope to Increase the Diagnostic Yield of Bronchoscopic Biopsy. *American Journal of Respiratory and Critical Care Medicine* 2013;187(2):125–9 doi 10.1164/rccm.201208-1483OE. [PubMed: 23322794]
26. Tan KM, Shishkov M, Chee A, Applegate MB, Bouma BE, Suter MJ. Flexible Transbronchial Optical Frequency Domain Imaging Smart Needle for Biopsy Guidance. *Biomedical Optics Express* 2012;In press.
27. Scolaro L, Lorensen D, McLaughlin RA, Quirk BC, Kirk RW, Sampson DD. High-sensitivity anastigmatic imaging needle for optical coherence tomography. *Opt Lett* 2012;37(24):5247–9 doi 10.1364/OL.37.005247. [PubMed: 23258067]

28. Kuo WC, Kim J, Shemonski ND, Chaney EJ, Spillman DR Jr., Boppart SA Real-time three-dimensional optical coherence tomography image-guided core-needle biopsy system. *Biomed Opt Express* 2012;3(6):1149–61 doi 10.1364/BOE.3.001149. [PubMed: 22741064]
29. Wells WA, Thrall M, Sorokina A, Fine J, Krishnamurthy S, Haroon A, et al. In Vivo and Ex Vivo Microscopy: Moving Toward the Integration of Optical Imaging Technologies Into Pathology Practice. *Arch Pathol Lab Med* 2018 doi 10.5858/arpa.2018-0298-RA.
30. Wolman M, Kasten FH. Polarized light microscopy in the study of the molecular structure of collagen and reticulin. *Histochemistry* 1986;85(1):41–9. [PubMed: 3733471]
31. Nadkarni SK, Pierce MC, Park BH, de Boer JF, Whittaker P, Bouma BE, et al. Measurement of collagen and smooth muscle cell content in atherosclerotic plaques using polarization-sensitive optical coherence tomography. *J Am Coll Cardiol* 2007;49(13):1474–81 doi 10.1016/j.jacc.2006.11.040. [PubMed: 17397678]
32. de Boer JF, Milner TE. Review of polarization sensitive optical coherence tomography and Stokes vector determination. *Journal of biomedical optics* 2002;7(3):359–71 doi 10.1117/1.1483879. [PubMed: 12175285]
33. Park BH, Pierce MC, Cense B, de Boer JF. Jones matrix analysis for a polarization-sensitive optical coherence tomography system using fiber-optic components. *Opt Lett* 2004;29(21):2512–4. [PubMed: 15584278]
34. Oh WY, Vakoc BJ, Yun SH, Tearney GJ, Bouma BE. Single-detector polarization-sensitive optical frequency domain imaging using high-speed intra A-line polarization modulation. *Optics Letters* 2008;33(12):1330–2 doi 10.1364/OL.33.001330. [PubMed: 18552948]
35. Oh WY, Yun SH, Vakoc BJ, Shishkov M, Desjardins AE, Park BH, et al. High-speed polarization sensitive optical frequency domain imaging with frequency multiplexing. *Optics Express* 2008;16(2):1096–103 doi 10.1364/OE.16.001096. [PubMed: 18542183]
36. Villiger M, Lorenser D, McLaughlin RA, Quirk BC, Kirk RW, Bouma BE, et al. Deep tissue volume imaging of birefringence through fibre-optic needle probes for the delineation of breast tumour. *Sci Rep* 2016;6:28771 doi 10.1038/srep28771. [PubMed: 27364229]
37. South FA, Chaney EJ, Marjanovic M, Adie SG, Boppart SA. Differentiation of ex vivo human breast tissue using polarization-sensitive optical coherence tomography. *Biomed Opt Express* 2014;5(10):3417–26 doi 10.1364/BOE.5.003417. [PubMed: 25360360]
38. Patel R, Khan A, Quinlan R, Yaroslavsky AN. Polarization-sensitive multimodal imaging for detecting breast cancer. *Cancer Res* 2014;74(17):4685–93 doi 10.1158/0008-5472.CAN-13-2411. [PubMed: 24958468]
39. Burns JA, Kim KH, deBoer JF, Anderson RR, Zeitel SM. Polarization-sensitive optical coherence tomography imaging of benign and malignant laryngeal lesions: an in vivo study. *Otolaryngol Head Neck Surg* 2011;145(1):91–9 doi 10.1177/0194599811403078. [PubMed: 21493273]
40. Mogensen M, Joergensen TM, Nurnberg BM, Morsy HA, Thomsen JB, Thrane L, et al. Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists. *Dermatol Surg* 2009;35(6):965–72 doi 10.1111/j.1524-4725.2009.01164.x. [PubMed: 19397661]
41. Strasswimmer J, Pierce MC, Park BH, Neel V, de Boer JF. Polarization-sensitive optical coherence tomography of invasive basal cell carcinoma. *J Biomed Opt* 2004;9(2):292–8 doi 10.1117/1.1644118. [PubMed: 15065894]
42. Kim KH, Burns JA, Bernstein JJ, Maguluri GN, Park BH, de Boer JF. In vivo 3D human vocal fold imaging with polarization sensitive optical coherence tomography and a MEMS scanning catheter. *Optics Express* 2010;18(14):14644–53 doi 10.1364/OE.18.014644. [PubMed: 20639950]
43. Hariri LP, Applegate MB, Mino-Kenudson M, Mark EJ, Bouma BE, Tearney GJ, et al. Optical frequency domain imaging of ex vivo pulmonary resection specimens: obtaining one to one image to histopathology correlation. *J Vis Exp* 2013(71) doi 10.3791/3855.
44. Yun S, Tearney G, Bouma B, Park B, de Boer J. High-speed spectral-domain optical coherence tomography at 1.3 μ m wavelength. *Opt Express* 2003;11(26):3598–604 doi 10.1364/OE.11.003598. [PubMed: 19471496]

45. Yun S, Tearney G, de Boer J, Bouma B. Removing the depth-degeneracy in optical frequency domain imaging with frequency shifting. *Opt Express* 2004;12(20):4822–8 doi 81308 [pii]. [PubMed: 19484034]
46. Villiger M, Zhang EZ, Nadkarni SK, Oh W-Y, Vakoc BJ, Bouma BE. Spectral binning for mitigation of polarization mode dispersion artifacts in catheter-based optical frequency domain imaging. *Opt Express* 2013;21(14):16353–69 doi 10.1364/OE.21.016353. [PubMed: 23938487]
47. Rich L, Whittaker P. Collagen and Picrosirius Red Staining: A polarized light assessment of fibrillar hue and spatial distribution. 2005 97–104 p.
48. MacKenna DA, Omens JH, McCulloch AD, Covell JW. Contribution of collagen matrix to passive left ventricular mechanics in isolated rat hearts. *The American journal of physiology* 1994;266(3 Pt 2):H1007–18 doi 10.1152/ajpheart.1994.266.3.H1007. [PubMed: 8160804]
49. Adams DC, Pahlevaninezhad H, Szabari MV, Cho JL, Hamilos DL, Kesimer M, et al. Automated segmentation and quantification of airway mucus with endobronchial optical coherence tomography. *Biomed Opt Express* 2017;8(10):4729–41 doi 10.1364/BOE.8.004729. [PubMed: 29082098]
50. Lattouf R, Younes R, Lutomski D, Naaman N, Godeau G, Senni K, et al. Picrosirius Red Staining: A Useful Tool to Appraise Collagen Networks in Normal and Pathological Tissues. *Journal of Histochemistry & Cytochemistry* 2014;62(10):751–8 doi 10.1369/0022155414545787. [PubMed: 25023614]
51. Street JM, Souza ACP, Alvarez-Prats A, Horino T, Hu X, Yuen PST, et al. Automated quantification of renal fibrosis with Sirius Red and polarization contrast microscopy. *Physiological Reports* 2014;2(7):e12088 doi 10.14814/phy2.12088. [PubMed: 25052492]

Statement of Translational Relevance

Biopsy samples must have sufficient tumor for all required histological and molecular diagnostic testing, particularly in lung carcinomas. However, contamination from tumor-associated fibrosis can yield inadequate biopsies and necessitate repeat procedures. Research biobanking also suffers from fibrosis contamination reducing tumor yields. The ability to detect and distinguish fibrosis from tumor at the time of collection could significantly improve tumor yield in all these settings. In this study, we demonstrated that polarization sensitive OCT (PS-OCT) can accurately identify and distinguish tumor-associated fibrosis from tumor using birefringence detection. Our results demonstrate a strong correlation between PS-OCT and matched histology for fibrosis quantification. We demonstrate that PS-OCT can reliably distinguish tumor regions with low fibrosis (< 20%) from those with >20% fibrosis. PS-OCT has significant potential for impact by increasing tumor yield for clinical and research purposes, either *in vivo* via needle-based imaging for biopsy guidance and/or *ex vivo* for rapid biopsy adequacy assessments.

Figure 1: Relationship between fibrosis detection in PS-OCT and PSR staining.
A high positive correlation ($r = 0.793$) is demonstrated between PS-OCT and PSR for quantifying percent fibrosis within the ROI. The dotted lines show 95% prediction intervals.

Figure 2. Bland-Altman plot for low fibrosis cases.

The dotted lines indicate the upper and lower 95% confidence intervals, and the red line indicates the bias. In the analysis of the low fibrosis (< 20% fibrosis) cases, there is minimal bias of -0.338% .

Figure 3. PS-OCT and PSR images of lung carcinomas with fibrosis.

(A) PS-OCT image of a squamous cell carcinoma (SCC) with dense birefringent fibrosis (F) on the right side, confirmed by (B) corresponding PSR staining (F). The left side of the image contains little birefringent fibrosis, indicating this region is likely to yield higher tumor content in a biopsy sample. (C) PS-OCT image of an adenocarcinoma with focal birefringent fibrosis (F), with (D) corresponding PSR staining confirming the focus of fibrosis (F) in the same ROI region. PS-OCT detects fibrosis and provides microscopic mapping of tumor/fibrosis distribution within a nodule, which would be useful in guiding biopsy sampling locations. Scalebars: 0.5 mm. PS-OCT images (A, C) display the measured birefringence overlaid on the corresponding structural OCT image. Birefringence map on left hand side indicates amount of birefringence in PS-OCT in degrees/100 μm (range 0-65 degrees/100 μm).

Figure 4. PS-OCT and PSR images of lung carcinomas with minimal to no fibrosis. (A) PS-OCT image of a non-invasive lepidic adenocarcinoma, with minimal interstitial birefringent fibrosis present throughout the ROI. (B) PSR staining confirms minimal fibrosis within alveolar walls, which is typical of lepidic adenocarcinoma pattern histologically. (C) PS-OCT image of a squamous cell carcinoma with solid morphology. Essentially no birefringent collagen was seen on PS-OCT imaging, (D) confirmed by PSR staining. PS-OCT detects tumor regions with little to no contaminant fibrosis, indicating adequate biopsy site locations, and can also provide some microarchitectural insights into the morphologic patterns of the carcinoma. Scalebars: 0.5 mm. PS-OCT images (A, C) display the measured birefringence overlaid on the corresponding structural OCT image. Birefringence map on left hand side indicates amount of birefringence in PS-OCT in degrees/100 μm (range 0-65 degrees/100 μm).

Table 1.**Clinical Characteristics.**

Age	71 years (range 57 - 84 years)
Sex	14 F/9 M
Diagnosis	
Adenocarcinoma	30 samples (14 patients)
SCC	24 samples (6 patients)
Carcinoid	2 samples (2 patients)
Hamartoma	1 sample (1 patients)
Size of lesion	3.1 mm (range: 1.2 - 6.3 mm)
Stage	
pT1a	4 patients
pT1b	5 patients
pT2a	7 patients
pT2b	2 patients
pT3	4 patients
N status	
Nx	3 patients
N0	17 patients
N1	1 patient
N2	1 patient

Table 2.
Fisher's exact contingency table: classifying tumor regions by fibrotic content with PS-OCT versus PSR.

Fisher's exact test demonstrated PS-OCT accurately classified tumor regions with low fibrosis content (20%) from those with > 20% fibrosis ($p < 0.0001$), with few false positive and negative cases. The sensitivity and specificity of PS-OCT for low fibrosis tumor regions (20%) was 0.95 and 0.80, respectively. The overall classification accuracy was 0.91.

	PS-OCT			
		20%	> 20%	Total
PSR	20%	40	2	42
	> 20%	3	12	15
	Total	43	14	57